Advertisement
AZN vs BIIB
Which Stock Would AI Choose? AstraZeneca (AZN) vs. Biogen (BIIB) Stock Comparison
Key Takeaways
- AstraZeneca (AZN) is a diversified global biopharmaceutical giant with a roughly $266 billion market capitalization, while Biogen (BIIB) is a much smaller, neuroscience-focused biotech valued near $35 billion.
- AZN pairs a deep oncology and respiratory pipeline with a ~2.5% dividend yield; BIIB carries no comparable income component and trades on a much higher trailing price-to-earnings (P/E) ratio.
- Both stocks have seen volatile recent weeks driven by clinical readouts, but BIIB has shown stronger short-term momentum on renewed pipeline optimism, even as its near-term earnings face year-over-year pressure.
- AZN's diversified revenue base offers broader stability, while BIIB offers higher potential upside tied to specific late-stage catalysts in lupus and kidney disease.
- For further detail, explore AZN Major News and AZN Today's Price Move, along with BIIB Major News and BIIB Today's Price Move.
- To see how automated strategies are positioning across these and thousands of other tickers, explore Trending AI Robots.
Introduction
Investors comparing AZN and BIIB are weighing two very different profiles within the healthcare sector. AstraZeneca is a diversified, income-generating pharmaceutical leader with operations spanning oncology, cardiovascular, respiratory, and rare diseases. Biogen is a concentrated biotechnology company whose fortunes are closely tied to a narrower neuroscience and immunology pipeline. This stock comparison is most relevant to investors deciding between broad-based defensive exposure and a higher-risk, higher-reward bet on clinical milestones. Understanding their relative performance, growth drivers, and risk profiles helps clarify how each might fit different portfolio objectives and time horizons in the current market environment.
AZN Overview and Recent Performance
AstraZeneca (AZN) is one of the world's largest biopharmaceutical companies, headquartered in the United Kingdom and heavily weighted toward oncology, where drugs such as Tagrisso, Imfinzi, and Enhertu anchor a broad revenue base. Recent market activity has been choppy, with the shares trading well below their 52-week high despite a market capitalization near $266 billion and a modest dividend yield around 2.5%.
Sentiment in recent weeks has been shaped by a mix of clinical headlines. The U.S. Food and Drug Administration (FDA) granted accelerated approvals, including Ultomiris in IgA nephropathy (a kidney disease) and sunvozertinib for a form of lung cancer. Positive data from Tagrisso plus savolitinib in lung cancer and from Imfinzi combinations in bladder cancer supported the oncology franchise. However, a Phase III miss for efzimfotase alfa in hypophosphatasia (a rare bone disease) tempered some of that enthusiasm. The company also completed an investment in Summit Therapeutics tied to the investigational drug ivonescimab, reflecting its continued push into next-generation oncology assets.
BIIB Overview and Recent Performance
Biogen (BIIB) is a Cambridge, Massachusetts-based biotechnology company focused on neurological and neurodegenerative diseases, with franchises in multiple sclerosis (MS, a disease affecting the brain and spinal cord), spinal muscular atrophy, and Alzheimer's disease. Its market capitalization is roughly $35 billion, far smaller than AstraZeneca's, which makes its share price more sensitive to individual pipeline outcomes.
BIIB has rallied notably in recent weeks, climbing toward the upper end of its 52-week range and outperforming its recent four-week trend. The move has been driven by growing optimism around its immunology pipeline. Positive 52-week Phase II data from the AMETHYST study of litifilimab in cutaneous lupus erythematosus (a form of lupus affecting the skin) strengthened confidence in that asset, while investors are also watching felzartamab in kidney disease and upcoming Phase III results for litifilimab in systemic lupus erythematosus (SLE). Several analysts raised price targets in response, though near-term earnings are still expected to decline year over year, reflecting patent-related and portfolio pressures.
Trending AI Robots
Tickeron's Trending AI Robots page curates a focused selection from a much larger library of AI-powered trading bots. Tickeron offers hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only the strategies best suited to current market conditions earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and set of tickers it trades, giving users a wide range of approaches to evaluate. Because these bots are filtered for suitability to prevailing conditions, the page provides a useful starting point for traders exploring automated tools without manually sifting through the full catalog. To review the currently featured strategies, visit the Trending AI Robots page.
Head-to-Head Comparison
The core contrast between these two names is diversification versus concentration. AstraZeneca's revenue spans multiple therapeutic areas and geographies, generating more than $58 billion in annual revenue and supporting a recurring dividend. Biogen's revenue is closer to $10 billion and is far more dependent on a handful of franchises, making it more vulnerable to individual product declines or clinical setbacks.
On growth drivers, AZN leans on a deep late-stage oncology pipeline and steady commercialization across established markets, with a forward P/E ratio near 16 that reflects its size and maturity. BIIB, by contrast, trades at a trailing P/E above 40, a premium that implies the market is pricing in future recovery from pipeline catalysts rather than current earnings power.
Momentum has diverged recently. BIIB has gained roughly 5-6% over the past month on pipeline enthusiasm, while AZN has moved more modestly amid a mixed run of clinical results. Risk profiles also differ: AZN carries execution and patent-expiry risk spread across a broad base, whereas BIIB carries concentrated binary risk tied to specific readouts, including litifilimab Phase III data expected around year-end.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst breadth, and relative positioning, Tickeron's AI would likely view AstraZeneca as the more stable, trend-consistent candidate, supported by its diversified revenue base, recurring dividend, and deeper pipeline. Biogen presents a stronger short-term momentum profile and higher potential upside, but with greater concentration risk and elevated valuation. In a probabilistic framework, the AI would likely favor AZN for risk-adjusted stability while acknowledging that BIIB's near-term catalysts could drive outsized moves if clinical data land favorably. The appropriate weighting depends on an investor's tolerance for volatility and reliance on single-asset outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Buy and BIIB is a Hold.
Momentum Indicator for AZN turns positive, indicating new upward trend
AZN saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In 51 of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AZN just turned positive on October 15, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 24 of 42 cases over the following month. The odds of a continued upward trend are 57%.
AZN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AZN crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +10.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 190 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 142 of 263 cases where AZN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The 10-day RSI Indicator for AZN moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 16 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 44%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
AZN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.749) is normal, around the industry mean (-1.421). P/E Ratio (27.660) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (1.168) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).
Momentum Indicator for BIIB turns positive, indicating new upward trend
BIIB saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 57 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 165 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 122 of 197 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for BIIB moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 20 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 58 cases where BIIB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for BIIB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In 35 of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.947) is normal, around the industry mean (-1.421). P/E Ratio (43.724) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
AZN | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 13 | 100 | |
SMR RATING 1..100 | 44 | 84 | |
PRICE GROWTH RATING 1..100 | 37 | 6 | |
P/E GROWTH RATING 1..100 | 54 | 3 | |
SEASONALITY SCORE 1..100 | 13 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZN's Valuation (65) in the Pharmaceuticals Major industry is in the same range as BIIB (76) in the Biotechnology industry. This means that AZN’s stock grew similarly to BIIB’s over the last 12 months.
AZN's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that AZN’s stock grew significantly faster than BIIB’s over the last 12 months.
AZN's SMR Rating (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (84) in the Biotechnology industry. This means that AZN’s stock grew somewhat faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (6) in the Biotechnology industry is in the same range as AZN (37) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to AZN’s over the last 12 months.
BIIB's P/E Growth Rating (3) in the Biotechnology industry is somewhat better than the same rating for AZN (54) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew somewhat faster than AZN’s over the last 12 months.
| AZN | BIIB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 44% | 1 day ago 71% |
| Stochastic ODDS (%) | 1 day ago 39% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 67% |
| MACD ODDS (%) | 1 day ago 57% | 1 day ago 58% |
| TrendWeek ODDS (%) | 1 day ago 45% | 1 day ago 68% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 65% |
| Advances ODDS (%) | 13 days ago 57% | 3 days ago 60% |
| Declines ODDS (%) | 1 day ago 45% | 9 days ago 67% |
| BollingerBands ODDS (%) | 1 day ago 43% | 1 day ago 73% |
| Aroon ODDS (%) | 1 day ago 54% | 1 day ago 62% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 1 FA rating(s) are green while BIIB’s FA Score has 2 green FA rating(s).
- AZN’s FA Score: 1 green, 4 red.
- BIIB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 6 TA indicator(s) are bullish while BIIB’s TA Score has 3 bullish TA indicator(s).
- AZN’s TA Score: 6 bullish, 4 bearish.
- BIIB’s TA Score: 3 bullish, 5 bearish.
Price Growth
AZN (@Pharmaceuticals: Major) experienced а +1.57% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -0.42% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.33%. For the same industry, the average monthly price growth was +2.53%, and the average quarterly price growth was +7.15%.
Reported Earning Dates
AZN is expected to report earnings on Feb 11, 2027.
BIIB is expected to report earnings on Feb 17, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-1.33% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
AZN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZN has been loosely correlated with BIIB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AZN | 1D Price Change % | ||
|---|---|---|---|---|
| AZN | 100% | -0.69% | ||
| BIIB - AZN | 48% Loosely correlated | +0.06% | ||
| GILD - AZN | 39% Loosely correlated | -0.67% | ||
| GSK - AZN | 28% Poorly correlated | -1.23% | ||
| MRK - AZN | 26% Poorly correlated | -0.59% | ||
| NVS - AZN | 26% Poorly correlated | -1.80% | ||
More | ||||
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | +0.06% | ||
| AMGN - BIIB | 50% Loosely correlated | +0.62% | ||
| AZN - BIIB | 49% Loosely correlated | -0.69% | ||
| PFE - BIIB | 48% Loosely correlated | +0.31% | ||
| MRK - BIIB | 46% Loosely correlated | -0.59% | ||
| GILD - BIIB | 42% Loosely correlated | -0.67% | ||
More | ||||